1. Home
  2. SA vs NUVB Comparison

SA vs NUVB Comparison

Compare SA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seabridge Gold Inc. (Canada)

SA

Seabridge Gold Inc. (Canada)

HOLD

Current Price

$33.83

Market Cap

3.7B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.58

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SA
NUVB
Founded
1979
2018
Country
Canada
United States
Employees
N/A
291
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
1.6B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
SA
NUVB
Price
$33.83
$4.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$65.00
$11.22
AVG Volume (30 Days)
769.3K
4.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$182.76
Revenue Next Year
N/A
$91.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.40
$1.57
52 Week High
$40.06
$9.75

Technical Indicators

Market Signals
Indicator
SA
NUVB
Relative Strength Index (RSI) 48.29 35.41
Support Level $28.46 $4.04
Resistance Level $40.06 $5.73
Average True Range (ATR) 1.83 0.33
MACD -0.43 -0.04
Stochastic Oscillator 25.68 24.78

Price Performance

Historical Comparison
SA
NUVB

About SA Seabridge Gold Inc. (Canada)

Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: